Navigation Links
Drug blocks two of world's deadliest emerging viruses
Date:3/5/2009

NEW YORK (March 5, 2009) -- Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology. Due to the study's significance, a manuscript was published yesterday online, in advance of the print issue, and will be highlighted as an editor's "spotlight" in the first May issue.

The two henipaviruses that are the subject of the study -- Hendra Virus (HeV) and Nipah Virus (NiV) -- emerged during the 1990s in Australia and Southeast Asia. Harbored by fruit bats, they cause potentially fatal encephalitis and respiratory disease in humans, with a devastating 75 percent fatality rate. More recently, NiV outbreaks in Bangladesh involving human-to-human transmission have focused attention on NiV as a global health concern.

The researchers, based in Weill Cornell's pediatrics department, were surprised by their discovery that chloroquine, a safe, low-cost agent that has been used to combat malaria for more than 50 years, is a highly active inhibitor of infection by Hendra and Nipah.

"The fact that chloroquine is safe and widely used in humans means that it may bypass the usual barriers associated with drug development and move quickly into clinical trials," says Dr. Anne Moscona, professor of pediatrics and microbiology & immunology at Weill Cornell Medical College and senior author of the study. She is also vice chair for research of pediatrics at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

"Chloroquine stands a good chance of making it through the development process in time to prevent further outbreaks of these deadly infections," adds Dr. Moscona.

Like the avian flu, SARS, and Ebola viruses, Hendra and Nipah are zoonotic pathogens. That means they originate in certain animals but can jump between animal species and between animals and humans. There are currently no vaccines or treatments against the two henipaviruses, which are listed by the U.S. government as possible bioterror agents.

Along with Dr. Moscona and her team, the study's lead author and fellow faculty member Dr. Matteo Porotto, in collaboration with Dr. Fraser Glickman at Rockefeller University's High Throughput Screening Resource Center, developed a screening test that substituted a non-lethal cow virus for the real thing. They engineered a viral hybrid, called a pseudotype, featuring proteins from the Hendra virus on its surface but lacking Hendra's genome. The pseudotype behaves in every way like its deadly counterpart, but ultimately, it only succeeds in replicating its non-lethal self.

The researchers designed their screening technique specially to reflect molecular reactions at several stages of the pathogen's lifecycle. Instead of focusing exclusively on how the virus enters the cell, like other pseudotyped screening assays, explains Dr. Porotto, the researchers were able to consider how Hendra matures, buds, and exits the cell, and to screen for compounds that interfere with its development at various stages.

Chloroquine does not prevent Hendra or Nipah virus from entering the cell. Instead, the chloroquine molecule appears to block the action of a key enzyme, called cathepsin L, which is essential to the virus's growth and maturation. Without this enzyme, newly formed Hendra or Nipah viruses cannot process the protein that permits the viruses to fuse with the host cell. Newly formed viruses then cannot spread the infection; in other words, they can invade, but cannot cause disease.

Several other zoonotic viruses depend on cathepsin L -- most notably, Ebola. "Our findings, and our methods, could easily be applied to the study of Ebola and other emerging diseases," Dr. Porotto says.

The researchers are confident that the use of this new screening strategy will build up the number of viral targets available for study and expand the antiviral research field at a time when new antivirals are desperately needed for emerging pathogens. The group anticipates collaborating on field studies in the near future, to assess the potential for efficacy of chloroquine and related compounds in Nipah-infected humans.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Drug blocks 2 of worlds deadliest emerging viruses
2. NLRB Blocks New Organizations Attempts to Divide UHW; SEIU UHW Committed to Securing Good Contracts With Members
3. Beta Blocker Blocks Feelings of Bad Memories
4. USC study finds that green tea blocks benefits of cancer drug
5. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
6. Experimental agent blocks prostate cancer in animal study
7. C5 Medical Werks Applies for Clearance, Certification and Licensing for the Global Marketing of ZirDent(TM) Ceramic CAD/CAM Dental Blocks
8. Monkey Gene That Blocks AIDS Viruses Evolved More Than Once
9. Iowa State chemists track how drug changes, blocks flu virus
10. Super-Thin Drug-Free Coating Hides Stent as It Unblocks Heart Arteries
11. Grape powder blocks genes linked to colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: